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Abstract 
Paracetamol (acetaminophen, APAP) is the most frequently used analgesic drug worldwide. 
However, patients in several specific populations can have an increased exposure to toxic APAP 
metabolites. Therefore, APAP-protein adducts have been proposed as an alternative marker for the 
assessment of APAP intoxications and as an effective tool to study and steer APAP treatment in 
patients with an increased risk of APAP-induced liver damage. These adducts have been determined 
in plasma or serum as a matrix. Blood microsampling allows the determination of a variety of 
analytes, including protein adducts, in a drop of blood, facilitating convenient follow-up of patients in 
a home-sampling context, as well as repeated sampling of pediatric patients. We therefore evaluated 
the use of blood-based volumetric microsamples for the quantification of APAP-protein adducts. 
Quantitative methods for the determination of APAP-protein adducts in dried blood and dried 
plasma volumetric absorptive microsamples were developed and validated. Also a preliminary 
evaluation of pediatric patient dried blood microsamples was conducted. Method validation 
encompassed the evaluation of selectivity, carry over, calibration model, accuracy and precision, 
matrix effect, recovery and the effect of the hematocrit on the recovery, dilution integrity, and 
stability. All pre-set acceptance criteria were met, except for stability. Spiking of blank blood with 
APAP revealed a concentration-dependent ex vivo formation of APAP-protein adducts, resulting in a 
response for the measurand APAP-Cys, with an apparent role for the red blood cell fraction. Analysis 
of authentic samples, following intake of APAP at therapeutic dosing, revealed much higher APAP-Cys 
concentrations in dried blood vs. dried plasma samples, making interpretation of the results in the 
context of published intervals difficult. In addition, in contrast to what was observed during method 
validation, the data obtained for the patient samples showed a high and unacceptable variation. 
We conclude that, for a combination of reasons, dried blood is not a suitable matrix for the 
quantification of APAP-protein adducts via the measurement of the APAP-Cys digestion product. The 
collection of plasma or serum, either in the form of a liquid sample or a dried microsample for this 
purpose is advised. 
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1. Introduction 
For decades, the Rumack-Matthew nomogram (with its subsequent adaptions) has been the 
reference tool for treatment decision in paracetamol (acetaminophen, APAP) intoxications (Rumack 
and Matthew, 1975; Wallace et al., 2002). This nomogram, while being a straightforward evaluation 
tool that is used on a daily basis in emergency departments all over the globe, also has several 
limitations. For example, it can only be used for the assessment of acute intoxications, the stated 
timing of ingestion and ingested dose of APAP are often unreliable, and the effect of risk factors for 
the development of APAP-induced liver failure is difficult to evaluate. In addition, patients often 
present themselves at the emergency department only upon manifestation of the toxicity symptoms, 
which can be many hours to days post-ingestion of APAP. As in these cases APAP may already have 
been eliminated from the blood, this may lead to a more complex management of the intoxication 
(Wallace et al., 2002). Therefore, APAP-protein adducts have been put forward as an alternative 
marker for the assessment of APAP intoxications (Bond, 2009). Several publications have confirmed 
the usefulness of these protein adducts in the assessment of an intoxication in various patient 
populations (Davern et al., 2006; Heard et al., 2017; Heard et al., 2016; Heard et al., 2011; James et 
al., 2006; James et al., 2008). A cut-off value in plasma for the treatment with the antidote N-
acetylcysteine has been proposed at 1.1 µM of protein-adduct derived APAP-Cysteine (APAP-Cys, a 
frequently measured digestion product of APAP-protein adducts)(James et al., 2009). In addition to 
the utility of these APAP-protein adducts in the decision-making process for treating APAP 
intoxications, these adducts may also be an effective tool to study and steer APAP treatment in 
patients for whom the dosing regimen might require an adaptation, e.g. children, elderly, morbidly 
obese patients, and patients with liver disease (Hayward et al., 2016; van Rongen et al., 2016). 
The formation of these APAP-protein adducts results from the covalent binding of N-acetyl-p-
benzoquinone imine (NAPQI) to Cys residues in proteins. NAPQI is a highly reactive metabolite of 
APAP, mainly formed via oxidation by hepatic CYP2E1 enzymes. Under therapeutic dosing, NAPQI will 
be detoxified via binding with glutathione (GSH), but in case of an intoxication, excess amounts of 
NAPQI are present and the GSH pool will be depleted. As a result, NAPQI will covalently bind to both 
proteins in the liver, causing hepatotoxicity, as well as to human serum albumin (HSA). The latter can 
be measured and may serve as a marker for APAP-induced hepatotoxicity (Bond, 2009; James et al., 
2003). Because of their specificity, long half-life and high abundance, APAP-protein adducts 
overcome the limitations of the current approach for the treatment decision making in paracetamol 
toxicity (Bond, 2009; Sabbioni and Turesky, 2017). 
As far as we are aware, all currently developed methods for the detection and quantification of 
APAP-protein adducts make use of serum or plasma as a matrix (Cook et al., 2015; Damsten et al., 
2007; Geib et al., 2018; Hoos et al., 2007; Muldrew et al., 2002). However, when envisaging the use 
of APAP-protein adducts for helping to steer APAP therapy, microsampling is beneficial, as multiple 
samplings may be required. In addition, microsampling would allow home-sampling for the follow-up 
of patients, and has also proven its added-value in pediatric patients, owing to its minimal 
invasiveness and the small volumes that are collected (Dorofaeff et al., 2016; Guerra Valero et al., 
2018). Although recently microsampling devices allowing for the generation of a dried plasma spot 
starting from capillary blood have come onto the market, dried blood-based microsamples, such as 
classical dried blood spots or volumetric absorptive microsamples are more extensively evaluated 
and more economic alternatives (Velghe et al., 2019). In volumetric absorptive microsampling 
(VAMS), a fixed volume of blood is wicked up by a polymeric tip fixed on a plastic handle. 
In this study, we evaluated the suitability of dried blood VAMS samples as an alternative matrix for 
the quantification of APAP-protein adducts. For this purpose, a method for the quantification of 
APAP-protein adducts in VAMS was developed and validated, for blood as well as plasma. Next, the 
method was applied on dried blood VAMS samples collected in a clinical setting, to evaluate the 
performance of the method via the analysis of real-life patient samples. 
2. Materials & methods 
2.1. Chemicals and materials 
APAP-Cys trifluoroacetic acid salt ( 97 % purity), used for the generation of calibrators, was obtained 
from Santa Cruz Biotechnology (Dallas, TX, USA), whereas APAP-Cys trifluoroacetic acid salt (95% 
purity), used for the generation of QCs, was procured from Toronto Research Chemicals (North York, 
Canada). The internal standard (IS) APAP-Cys-d5 trifluoroacetic acid salt was also obtained from 
Santa Cruz Biotechnology. Methanol and acetonitril (both LC-MS grade) were purchased from 
Biosolve (Valkenswaard, The Netherlands). Ultrapure water (18.2 MΩ resistivity) was generated in 
house, by a Synergy® Water Purification System (Merck Millipore, Overijse, Belgium). 10 µL Mitra 
VAMS devices were purchased from Neoteryx (Torrance, CA, USA). Protein LoBind 2 mL cups were 
obtained from Eppendorf (Hamburg, Germany). Formic acid (FA), ammonium bicarbonate (AMBIC, 
LC-MS grade), and pronase from Streptomyces griceus (Type XIV) were purchased from Sigma Aldrich 
(Diegem, Belgium). The Pierce BCA Protein assay kit was obtained from Thermo Fisher Scientific 
(Waltham, MA, USA). 
2.2. Standard solutions, calibrators, and quality control samples  
Blank EDTA-anticoagulated blood for the generation of blood and plasma VAMS samples, used for 
the preparation of calibrators and QC samples, was obtained from a healthy volunteer. The Hct of 
the blood was determined using a Sysmex XE-5000 hematology analyzer (Sysmex, Kobe, Japan). 
Plasma was generated by centrifugation of the blood (5 min at 5000 g). For the generation of blood 
samples with varying Hct, an aliquot of the blood was centrifuged (5 min at 5000 g), and plasma was 
removed or added. When blood or plasma were spiked with analyte prior to VAMS sampling, the 
non-matrix spiked volume was maximally 5 V/V%. Blood and plasma VAMS samples were prepared 
by dipping the lower part of the device tip in the sample until the tip was completely filled. After 
sampling, the devices were air-dried for at least 2 h, after which they were stored in an air-tight 
plastic bag containing desiccant.  
Stock solutions (1 mg/mL) for the generation of calibrators and QCs were prepared independently in 
methanol and further diluted with water/methanol (50/50 V/V%) to 1 mM and stored at -80 °C. On 
the day of analysis, spiking solutions were prepared by diluting the stock solutions with AMBIC 
(50 mM). A stock solution of the IS (500 ng/mL) was prepared similarly and stored at -80 °C until 
analysis. 
Calibrators were prepared at seven concentration levels for blood (0.25, 0.50, 1.0, 2.0, 5.0, 10 and 
25 µM), and eight levels for plasma VAMS samples (0.05, 0.10, 0.25, 0.50, 1.0, 2.0, 5.0 and 10 µM). 
Quality control (QC) samples were prepared at four concentration levels: 0.25  µM (Lower limit 
of quantification, LLOQ), 0.75 µM (Low QC), 5 µM (Mid QC), and 20 µM (High QC) for blood 
VAMS samples and 0.05 µM (LLOQ), 0.125 µM (Low QC), 1 µM (Mid QC), and 8 µM (High QC) for 
plasma VAMS samples. 
In addition to spiked QC samples, also non-spiked QC blood and plasma VAMS samples, referred to 
as native QCs, were used. Hereto, blood obtained from a healthy volunteer after ingestion of 
therapeutic doses of APAP was used. We also had access to a serum sample, obtained from a subject 
after an APAP overdose, which was diluted with blank blood or plasma, to generate native QCs at 
appropriate concentrations. For plasma, 4 native QC levels (LLOQ, Low, Mid, and High) were 
generated, whilst for blood 3 levels (Low, Mid, and High) of native QCs were prepared. These native 
QC samples were used for optimization of the method and for evaluation of different parameters in 
the method validation. 
2.3.  Sample preparation 
The existing methods which have been used the most for application on patient samples make use of 
the enzyme pronase to digest the APAP-protein adducts (Cook et al., 2015; McGill et al., 2011). This 
digestion procedure is typically executed on a selected protein fraction (e.g. obtained via dialysis, gel 
filtration or HiTrap Blue HP affinity columns) and results in the release of APAP-Cys (further referred 
to as APAP-Cysprot), a single Cys amino acid covalently bound to NAPQI, which can then be quantified. 
However, in blood free and GSH-derived Cys(formed by hydrolysis) could also give rise to the 
formation of APAP-Cys after covalent binding with NAPQI (further referred to as APAP-Cysfree). 
Hence, it was essential to include a wash step in the sample preparation procedure to eliminate 
APAP-Cysfree during sample preparation. 
The method development included the evaluation of different wash solvents, temperature, wash 
time per cycle and number of wash cycles. The blood VAMS samples used for optimization of the 
wash procedure were prepared from blank blood spiked with APAP-Cys at a concentration of 
5 µg/mL. As in this step, the aim was to wash away as much as possible APAP-Cysfree, the reduction of 
the signal after application of the different wash procedures was evaluated, as well as the %RSD of 
the replicates (n=3) for each condition. Next, the performance of the wash procedure for blood and 
plasma VAMS samples was verified based on the analysis of native High QCs. For this purpose, the 
samples were processed following the optimized wash procedure, followed by an incubation step 
with and without pronase (100 µL AMBIC, 50 mM was added instead), to evaluate the presence of 
any remaining APAP-Cysfree. After optimization of the wash procedure, we also determined to what 
extent blood proteins were lost during this step, via a Pierce BCA Protein assay, following the 
manufacturer’s instructions. This colorimetric assay was performed using blood VAMS samples with 
different Hcts (19.9 %, 28.6 %, 38.8 %, 48.3 %, 57.8 %) to evaluate the protein loss at each Hct level 
(n=3 per Hct level). For each Hct, the total protein was determined by extracting the VAMS samples 
(n=2) with water. The wash solvents were collected after each wash step, evaporated and 
reconstituted in water to be compatible with the assay. After determination of the protein 
concentration, the percentage of protein in each wash solvent compared to the total protein per Hct 
was calculated. 
For the optimization of the digestion, the amount of pronase, digestion time, and temperature were 
evaluated. For this purpose, blood from a healthy volunteer after ingestion of 5 g APAP over 30 h was 
used. The signal for APAP-Cys, as well as the %RSD of the replicates (n=3) per condition were 
evaluated. 
To verify whether the chosen digestion procedure maximally generates the digestion product APAP-
Cys, 3 VAMS samples, generated from the same blood, were incubated with pronase according to the 
optimized digestion procedure, followed by a second addition of pronase and additional incubation 
for 7.5 h. The analyte/IS area was compared to that of 3 VAMS samples incubated following only the 
optimized digestion procedure. 
As we aimed at setting up a procedure for the combined determination of APAP and APAP-
protein adducts, the sample preparation for the quantitation of APAP precedes the wash and 
digestion steps described above (Delahaye et al., 2019). In short, the VAMS sample tips are 
removed from the handle and extracted in a 2 mL LoBind cup with 300 µL extraction solvent 
(methanol/water/FA - 80/20/0.01), of which 250 µL is diluted with water (0.01% FA) to a total 
volume of 1.0 mL and injected onto the LC-MS/MS. The remaining extraction solvent (50 µL) is 
then removed from the cup, after which the wash procedure and the digestion take place. For 
the digestion, 100 µL of pronase solution is added, together with 100 µL AMBIC (50 mM) for 
patient samples, blanks, zero samples, and native QCs, or 100 µL of spiking solution for 
calibrators and spiked QCs. After the optimized digestion procedure, the remaining proteins are 
precipitated with 400 µL methanol, containing the IS APAP-Cys-d5 (6.25 ng/mL), followed by 
10 min shaking in a Thermomixer comfort (Eppendorf, Hamburg, Germany) (23 °C, 1400 rpm) 
and a centrifugation step (10 min, 10000 g, RT). Next, 500 µL of the supernatant is transferred 
to a glass tube for evaporation under nitrogen at 60 °C. Once the samples are dry, they are 
reconstituted with 65 or 100 µL AMBIC (50 mM) for the plasma samples and blood samples, 
respectively. 
2.4. Liquid chromatographic and mass spectrometric conditions  
The APAP-protein adducts were quantified via ultra-high performance liquid chromatography 
coupled to tandem mass spectrometry (UHPLC-MS/MS). The instrument set-up consisted of a Waters 
Acquity UPLC® (Waters, Milford, MA, USA) coupled to a SCIEX API 4000™ (SCIEX, Framingham, MA, 
USA). Data acquisition, processing and analysis were performed using Analyst 1.6.2 (SCIEX) and the 
Waters Acquity console. 
For chromatographic separation a Waters Acquity UPLC® HSS T3 column (1,8 µm; 2.1 X 100 mm) with 
a suitable Van-Guard column and a gradient run of 4.3 minutes is used, starting at 100% mobile 
phase A (water/methanol/FA - 95/5/0.01) and ramping up to 3% mobile phase B 
(acetonitrile/water/FA - 95/5/0.01) over 2 min. The gradient increases further to 18% mobile phase B 
over 0.2 min, and subsequently to 95% mobile phase B over 0.1 min and is kept at 95% mobile phase 
B for 1 min, returning immediately to 100% mobile phase A, followed by column re-equilibration for 
1 min. The column is kept at 45 °C, the autosampler is held at 10 °C, and the injection volume is 
10 µL. The mass spectrometer, equipped with a TurboIonSpray® source, uses electrospray ionization 
and operates in positive MRM mode. The MRM transitions for the quantifier ion (QI) and 
confirmation ion (CI) of the analyte and the IS, as well as the compound specific parameters are 
displayed in Suppl Table 1. The source and gas parameters of the method are summarized in Suppl 
Table 2. 
2.5. Method validation 
The methods were validated based on EMA and FDA guidelines for bioanalytical method validation 
and the Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology 
guideline on the ‘Development and Validation of Dried Blood Sample-based methods for Therapeutic 
Drug Monitoring’ (Capiau et al., 2019; European Medicines Agency, 2011; U.S. Department of Health 
and Human Services Food and Drug Administration, 2018). Selectivity, carry over, calibration model, 
accuracy and precision, matrix effect (ME), recovery and the effect of the Hct on the recovery, 
dilution integrity, and stability were evaluated. Each analytical run included the evaluation of a 
control blank (i.e. a blank sample processed without the addition of the IS) and zero sample (i.e. a 
blank sample processed with the addition of the IS), as well as spiked QC samples. 
The analyte/IS area ratio of the QI vs. nominal concentration is used for the construction of the 
calibration curves. Six calibration curves, run on six different days, were used for the evaluation of 
the best fitting calibration model. The model with the lowest sum % residual error (%RE) was 
selected. To accept this model, back-calculated concentrations of the calibrators were determined, 
which should differ less than 15% (20% for the LLOQ) from the nominal value for 75% of all 
calibrators.  
For the evaluation of carry over, blank samples were injected after the upper limit of quantification 
(ULOQ; n=3x2). The response at the retention time of APAP-Cys obtained in the blank samples should 
not exceed 20% of the LLOQ response and 5% of the IS response. 
The accuracy and precision were determined based on spiked QCs. The %bias was used for the 
assessment of the accuracy, whilst intra-day and total assay precision were determined via single 
factor analysis of variance (ANOVA), based on the CLSI-EP05-AC guideline (n=5x2)(Clinical and 
Laboratory Standards Institute, 2014). The acceptance criteria for the accuracy and precision were a 
%bias and %RSD lower than 15% and 20% for the LLOQ. In addition, we evaluated the precision of 
the method, based on the repeated analysis of native QCs (n=4x2). In contrast to the determination 
of spiked QCs, these measurements also take into account the variability of the wash and digestion 
procedure. 
Dilution integrity was evaluated by spiking blood and plasma VAMS samples (n=6) with APAP-Cys at a 
concentration of 100 µM and 40 µM, respectively. After reconstitution, the samples were diluted 5 
times with AMBIC (50 mM), and their concentration was compared to the nominal value. A maximum 
%bias of 15% was considered acceptable. 
The assessment of the ME was performed following the approach suggested by Matuszewski 
(Matuszewski et al., 2003). For this purpose, the same blank blood (n=8) and plasma samples (n=6) 
which were used for the selectivity, were processed and spiked with APAP-Cys in the reconstitution 
step at Low and High QC level, and compared to neat solvent (AMBIC, 50 mM) spiked with the same 
amount of analyte. The absolute analyte ME, absolute IS-compensated ME, and the relative ME were 
calculated. The latter is evaluated by calculation of the %RSD, which should not exceed 15%. 
The recovery of the blood VAMS samples was evaluated based on native samples at two analyte 
levels (determined as 0.37 µM and 2.97 µM APAP-Cys) and at 5 different Hct values (19.9%, 28.6%, 
38.8%, 48.3%, 57.8% for the low level and 16.3%, 26.6%, 36.8%, 46.6%, 58.8% for the high level), 
with 6 replicates per condition. The samples were prepared by adding blank blood with different Hcts 
to a fixed volume of the overdose case serum sample used for the generation of the native QCs. For 
plasma VAMS samples, the Low and High native QC samples were used (see Section 2.2) (n=6). The 
relative recovery was determined via repeated digestion of the samples, by calculating the relative 
contribution of the signal obtained after the first analysis compared to the sum of the signals of this 
and the two subsequent analyses. After the first digestion and protein precipitation cycle, the 
remaining solvent is removed from the cup, and new digestion solvent is added to the VAMS tip, 
allowing to digest and extract any possible remaining protein adducts. This step is repeated once 
more, to obtain a total of three digestion cycles per VAMS tip. The relative recovery at the different 
Hct levels was compared to that of the intermediate Hct (38.8% and 36.8%). An acceptance criterion 
of 15% deviation compared to the intermediate Hct was set. Furthermore, the %RSD at each Hct 
level should also be lower than 15%. 
For the evaluation of the selectivity, blank blood and plasma VAMS samples (n=6 for each matrix) 
from individual donors, as well as blank blood VAMS samples with either a low (19.1%) or high 
(57.6%) Hct, were analyzed. Identical criteria apply as for carry-over. In addition, the analyte ion ratio 
(QI/CI) of the calibrators was compared to the analyte ion ratio (QI/CI) of patient samples (n=6), to 
exclude the presence of interferences. An acceptance criterion of 30% deviation compared to the 
average ratio of the calibrators was set. Furthermore, blank blood and plasma were spiked with APAP 
at three concentration levels (5, 10, and 25 g/mL; n=3), and blank blood samples with adapted Hct 
levels (21.3%, 42.8%, and 65.2%; n=3) were spiked with APAP at one concentration level (80 g/mL). 
From the blood samples with adapted Hct, plasma was separated and VAMS samples (n=3) were 
generated. The samples were processed following the normal sample preparation procedure and the 
chromatograms were evaluated for the absence of interferences. 
The stability of the VAMS samples was assessed via native QCs at Low and High level, for both blood 
and plasma. Samples were stored up to 6 months at -20 °C, 4 °C, and room temperature (RT) and up 
to 1 month at 50 °C. All VAMS samples for the stability study were prepared on the same day, frozen 
at -80 °C, which was considered the reference temperature at which there is no degradation of the 
APAP-protein adduct, until storage at the desired temperature. All samples were analyzed in the 
same analytical run, together with samples stored at -80 °C for the complete storage time. The 
concentrations determined in the latter served as the reference concentrations (T0 concentrations). 
In addition, the stability of processed samples was evaluated after storage in the autosampler for 
3 days, after 3 freeze-thaw cycles and after storage at -80 °C for 3 weeks (n=3). The mean 
concentration per condition (n=3) should not deviate more than 15% compared to the concentration 
determined at T0. 
2.6. Application 
To evaluate the use of dried blood microsamples for the quantification of APAP-protein adducts, 
based on the analysis of patient samples, blood VAMS samples from pediatric patients (1 month to 
18 years old), admitted to the intensive care unit, and receiving intravenous APAP treatment, were 
collected at the Ghent University Hospital (EC approval B670201629325). Per patient, typically 10 
sampling time points were foreseen, spread over one or more days. The samples were collected via a 
central venous or arterial catheter, allowing the collection of a small amount of blood in a 2 mL cup. 
Subsequently, VAMS samples were prepared as described above (see Section 2.2). Per time point, 2 
to 4 VAMS samples were collected. These samples were stored at RT for a maximum of two weeks, in 
a plastic bag containing desiccant, after which they were further stored at -80 °C until analysis. In this 
patient population no plasma samples were collected. In total, 286 samples were analyzed, collected 
from 29 different patients. 
3. Results & discussion 
3.1. Sample preparation 
The first step of the sample preparation procedure encompasses the extraction of APAP (see Section 
2.3). As a result of this organic extraction step, the blood and plasma proteins are fixated on the 
VAMS tip. This provides the opportunity of eliminating smaller molecules, amongst which APAP-
Cysfree, from the device tip, whilst retaining the proteins, including the APAP-protein adducts. 
Following the extraction of APAP, a wash procedure is applied to remove APAP-Cysfree, as its presence 
interferes with the determination of the APAP-protein adducts via the measurement of APAP-Cysprot 
in the sample. This wash procedure was optimized to achieve a maximal removal of APAP-Cysfree. This 
was verified using blood VAMS samples spiked with APAP-Cys (5 µg/mL) prior to VAMS sampling, and 
evaluating the decrease in signal compared to unwashed VAMS, as well as the %RSD of the replicates 
(n=3) for each condition. Different wash solvents, temperatures, and wash times were investigated, 
as well as the influence of sonication (results not shown). This yielded the following wash procedure, 
chosen as it gave no detectable signal for APAP-Cysfree: two 30’ washes of the samples by shaking in a 
Thermomixer comfort (80 °C, 1000 rpm) with 1.5 mL of wash solvent (water/methanol/FA - 
50/50/0.01). For the plasma VAMS samples, the same wash procedure was applied without further 
adaptation. The performance of the wash procedure was also verified using native QC blood and 
plasma VAMS samples (n=3) at the High QC level. While a prominent peak corresponding to APAP-
Cysfree was present in unwashed non-digested samples (Figure 1, panels A and B), APAP-Cysfree was no 
longer detectable after application of the wash procedure (Figure 1, panels C and D). This indicates 
that the wash procedure efficiently removes the APAP-Cysfree from the samples. In contrast, a clear 
signal is observed after incubation with pronase, demonstrating that after application of the wash 
procedure the APAP-protein adducts are still available for digestion (Figure 1, panels E and F). 
Next, a Pierce BCA Protein assay was performed, to determine the loss in proteins during the wash 
procedure for blood VAMS samples. In Figure 2 the results of this assay are presented, which 
revealed that there was between 11.7% and 17.7% total protein loss during the wash procedure. The 
majority of the proteins are detected in the wash solvent of the first wash cycle, while in the second 
wash cycle the loss of proteins is markedly lower. There are no distinct differences in protein loss 
between samples with a different Hct. However, it needs to be noted that part of the proteins which 
are lost in the wash procedure will include the APAP-protein adduct of interest. Since spiking with 
APAP-Cys in the calibrators is only performed after the wash procedure, this inherent loss of APAP-
protein adducts is not mirrored via the calibrators. Other published procedures cope with a similar 
issue: e.g. also when HSA is captured on a HiTrap Blue HP affinity column, the recovery will not be 
100%. Given the lack of availability of labeled APAP-adducted HSA, this is an intrinsic limitation. 
Optimization of the digestion procedure encompassed an evaluation of the amount of pronase, 
incubation temperature and time. As for the wash procedure, the calibrators cannot correct for any 
variation in digestion efficiency, as spiking of the calibrators is performed with APAP-Cys, and not 
with the intact APAP-protein adduct. Hence, the digestion efficiency needs to be maximized and 
needs to be reproducible. 
An overnight digestion (approximately 16 h) at 37 °C under gentle shaking with 600 µg pronase 
(corresponding to 3 Units) per sample was selected as the optimal digestion condition. The %RSD for 
the samples (n=3) incubated under these conditions was 7.9%, indicating that the digestion is 
reproducible.  
When adding additional pronase to 3 blood VAMS samples and incubating for another 7.5 h, there 
was no increase in signal for APAP-Cys compared to VAMS samples only incubated overnight without 
additional pronase, indicating that maximal digestion efficiency has been obtained with the selected 
digestion procedure (One-way ANOVA, =0.05, p=0.35). 
3.2. Method validation 
The calibration model using a linear calibration with 1/x2 weighting resulted in the lowest %RE for 
both blood and plasma. When applying this calibration model for the back-calculation of the blood 
and plasma VAMS calibrator samples, respectively two and one calibrator(s) had a deviation of more 
than 15% from their nominal value, fulfilling the pre-set acceptance criteria. Hence, the linear model 
could be accepted. 
No carry-over was observed upon injection of blank samples after the ULOQ calibrator samples 
(n=3x2). 
Table 1 summarizes the results for the accuracy and precision, based on the measurement of spiked 
QC samples, and the precision obtained from the analysis of native QC blood and plasma VAMS 
samples. The intra-day precision of the spiked QC VAMS samples did not exceed 10%, and for the 
total precision the %RSD was below 14% for all spiked QC levels. For the accuracy of the spiked QC 
samples, all QC levels had a %bias less than 8%. The total precision obtained via the analysis of native 
QCs was below 15% for all QCs. Therefore, the accuracy and precision fulfilled the pre-set acceptance 
criteria, both for the spiked QC samples and the native QC samples. 
Evaluation of the dilution integrity revealed that the average bias for the blood and plasma VAMS 
samples (n=6), diluted 5 times with AMBIC (50 mM), was 0.75% and 6.9%, respectively, with a %RSD 
of 2.5% and 4.5%, respectively. Thereby, the acceptance criteria were fulfilled. 
The results of the ME experiment (Table 2) revealed that for both the blood and plasma VAMS 
samples a high analyte ME was observed. However, this ME was almost completely compensated for 
by the IS, and also the IS-compensated relative ME fulfilled the preset acceptance criteria, with a 
maximal %RSD of 8.4%. 
Given the absence of labeled APAP-adducted HSA, an alternative approach had to be followed to 
assess recovery. An approach was used which determines the relative recovery, based on the 
repeated digestion of native samples. This approach does not allow to determine the absolute 
recovery, which is a more common approach in bioanalytical method validation, but allows to verify 
whether the recovery is consistent over different analyte levels, and, importantly, over different 
Hcts. The results, displayed in Figure 3, reveal that the recovery is slightly decreasing with an 
increasing Hct, however, not more than the pre-set acceptance criterion of 15% compared to the 
intermediate Hct. A t-test (α = 0.05) did not reveal a statistically significant difference between the 
recovery at low and high analyte level for intermediate Hct samples (p=0.1692). Furthermore, the 
obtained values are consistent within each condition, with a maximum %RSD of 5.2%. Hence, the 
sample preparation procedure yields reproducible digestion and extraction efficiencies. This again 
confirms that maximum digestion efficiencies are obtained, as was also concluded earlier in the 
method development. For the third digestion cycle, no detectable signals for APAP-Cys were 
observed. Given the low number of patient samples with a Hct over 45%, we can expect that for the 
majority of the samples the digestion efficiency will approximate 100%. Again, this optimization is 
highly important, as in the calibrators there is no digestion involved and therefore, in the calibrators 
there is no compensation for the digestion efficiency. 
For the plasma VAMS samples, the average recovery was 95.6%, and 97.7% for the Low and High 
native QCs, respectively. A t-test (α=0.05) revealed a marginally statistically significant difference 
between both QC levels (p=0.0469), however, the 95% confidence interval of the difference ranged 
from 0.043% to 4.29%. Therefore, the difference between the recovery of the Low and High QC levels 
is limited and will not have a relevant influence on the results of the analysis of patient samples. 
No unacceptable interferences were observed in the analysis of the blank blood and plasma VAMS 
samples. The ion ratio (QI/CI) of the patient samples (n=6) was within 91-118% of the mean ion ratio 
of the calibrators analyzed in the same analytical run, fulfilling the pre-set acceptance criteria. 
When spiking APAP to blank blood and preparing VAMS samples from these spiked blood samples, a 
signal for APAP-Cys was obtained. This signal increased with increasing amounts of spiked APAP. 
Moreover, when spiking APAP to blood with different Hcts, the signal increased with increasing Hct 
(see Figure 4). When plasma was spiked with APAP at three concentration levels, no signal for APAP-
Cys was detected for the two lowest concentrations (5 and 10 µg/mL), and for the plasma samples 
spiked with 25 µg/mL the signal obtained was below the LLOQ of 0.05 µM, which is noticeably 
different from the results obtained with blood. 
After excluding external contamination or the formation of APAP-Cys during the sample preparation 
procedure, we concluded that the presence of APAP in blood can contribute to the formation of 
APAP-protein adducts, without any involvement of hepatic metabolization, as APAP is spiked to the 
blood ex vivo. In addition, the ion ratios (QI/CI) of the observed peaks match those of the calibrators 
and QCs. Hence, we believe that the detected signal is originating from APAP-Cysprot. As the signal of 
APAP-Cys increases with increasing Hct, and in plasma no signal, or signals below the LLOQ were 
obtained, it could be hypothesized that the ex vivo formation of APAP-protein adducts is facilitated 
by the presence of red blood cells and/or mainly occurs with Cys residues of blood-specific proteins 
and not with HSA. 
To confirm this hypothesis, blank blood samples with different Hcts were supplemented with an 
equal quantity of a blood sample from a healthy volunteer that had ingested therapeutic amounts of 
APAP. This healthy volunteer sample contained both APAP and APAP-protein adducts. The resulting 
blood samples had a Hct of 21.0%, 40.2%, and 60.2%. Subsequently, plasma was derived from these 
blood samples, as well as from the original positive blood sample (Hct 41.3%). VAMS samples were 
prepared from all blood (n=1) and plasma (n=3) samples. When comparing the concentrations of 
APAP-Cys in the blood VAMS samples, there was a significant increase in APAP-Cys when the Hct of 
the blood was adapted to 60% (Figure 5, left panel). However, when looking at the plasma VAMS 
samples derived from the adapted blood samples, there was no increase in APAP-Cys compared to 
the plasma VAMS samples derived from the original blood sample (Figure 5, right panel). These 
results point towards the ex vivo formation of APAP-protein adducts with blood specific proteins, due 
to the presence of APAP in blood, since there was no increase for the plasma VAMS samples. As far 
as we are aware, the method presented in this paper is the first to report on the formation of APAP-
protein adducts in blood and their determination in dried blood samples. No reference levels in 
blood are available for these adducts. 
To further investigate this observation, blank blood was spiked with APAP (7.5 µg/mL), and VAMS 
samples (n=3) were derived at different time points after spiking, to evaluate the kinetics of this 
adduct formation. This evaluation showed that the formation of APAP-protein adducts in the spiked 
blood occurs immediately after spiking and does not increase further with increasing incubation time 
(Suppl. Figure 1, left panel). In addition, the effect of the storage temperature on the additional 
formation of APAP-protein adducts in an authentic blood sample was evaluated. A venous blood 
sample from a healthy volunteer who took therapeutic doses of APAP was collected, aliquoted and 
stored at different temperatures (4 °C, RT, and 37 °C). After 1 h of storage, VAMS samples (n=3) were 
derived from the different blood samples. As can be deduced from the analysis of the authentic 
patient sample, the concentration of APAP-Cysprot in the blood samples was not considerably 
different when the blood was stored at the above-mentioned conditions after collection (Suppl. 
Figure 1, right panel). 
Since the formation of these additional protein adducts in blood complicates the interpretation of 
the the total APAP-Cys signal, it can be questioned to what extent the quantification of APAP-Cys in 
(dried) blood samples allows to verify the exposure to the toxic APAP metabolite NAPQI. The 
monitoring of other, larger digestion products than APAP-Cys, e.g. APAP-CPF or APAP-LQQCPFEDHVL, 
which are (more) specific for NAPQI-HSA adducts, might be considered to help to overcome this 
interpretative issue. 
The stability of blood and plasma VAMS samples was evaluated after storage for 6 months at -20 °C, 
4 °C, and RT, taking -80 °C as the reference, to assure limited contribution of variability in the results 
due to calibration or differences in sample preparation over different analysis days. When looking at 
the stability data after 6 months storage at the different storage temperatures (see Figure 6), the 
results for the plasma VAMS samples are within the pre-set acceptance criteria, except for the Low 
QC at 4 °C, where a higher signal was obtained. Also for the blood VAMS samples 6-month storage at 
4 °C yielded elevated concentrations. The result for the long term storage of the blood VAMS 
samples was within 15% acceptance limits for the High QC at -20 °C and RT and slightly above the 
acceptance limit for the Low QC at -20 °C. However, a 29% decrease in response was seen for long-
term storage of the Low QC at RT. 
The stability data obtained from the analysis of native plasma QC samples after 6 months storage 
indicate that there is no or only limited degradation of the APAP-protein adducts. Since the results 
for the blood VAMS samples indicated that further investigation of the stability was necessary, 
additional stability data were collected for blood and plasma VAMS samples stored for 7 days, 
1 month, and 3 months at -20 °C, 4 °C and RT, and for 1 day, 4 days, 7 days and 1 month at 50 °C. 
When examining the stability more into detail (Suppl Figure 2) many of the storage conditions for the 
blood VAMS samples resulted in average values above the acceptance limit of 115% compared to the 
result obtained at T0. The IS area was stable over all samples, indicating no issues with ME in these 
analyses. Hence, ion enhancement or suppression could not be the cause of the variability. More 
likely, these results could be explained by a decreased and/or more variable efficiency of the wash 
procedure, leading to an increased presence of APAP-Cysfree in the samples after the wash procedure, 
resulting in a notable increase in the measured concentrations in these samples. Previous reports in 
literature have indicated that the extraction of small molecules from VAMS samples can be 
dependent on the storage condition, which is in support of this theory (Delahaye et al., 2019; Xie et 
al., 2018). On the other hand, the results obtained for the stability of the blood VAMS samples after 
storage at 50 °C are all below or approximate the lower limit of acceptance. Hence, in these samples 
there appears to be no relevant contribution of APAP-Cysfree to the obtained results. A decreased 
extraction of APAP-Cysprot and/or a decreased digestion efficiency of the APAP-protein adduct may 
underlie this observation. No additional information on the long-term stability in blood or plasma of 
APAP-protein adducts is currently available in literature. For sulfur mustard-HSA adducts, it was 
demonstrated that storage for 9 days did not lead to any degradation of the protein adduct in both 
liquid and dried plasma samples (John et al., 2016).  
The results of the determination of the stability of the processed samples are presented in 
Suppl Fig 3. All results were within 15% of the determination at T0. The stability was evaluated after 
storage for 3 days in the autosampler, 3 freeze-thaw cycles and 3 weeks at -80 °C, allowing for re-
injection of the samples, if necessary. 
3.3. Application 
Although the results of the validation, and the experiments where APAP was spiked to blank blood, 
already indicated that dried blood might not be suitable for the determination of APAP-protein 
adducts via the measurement of APAP-Cys digestion products, the method was applied on patient 
samples, as these samples were already collected. Blood VAMS samples were generated from venous 
or arterial blood collected from pediatric patients admitted to the intensive care unit of Ghent 
University Hospital, who received intravenous APAP treatment. In total 286 blood VAMS patient 
samples were analyzed. Remarkably, these patient samples showed very large differences in IS area, 
both within and between patients and within and between different analysis days. These findings 
contrasted with the results obtained during method development and validation, in which consistent 
IS areas were obtained for the calibrators, spiked QCs and native QCs, throughout all analysis days. 
Different patient characteristics such as age, Hct and HSA concentration were evaluated, but no 
correlation was found. Also the sample age was excluded as a reason for the decrease in IS area. 
Some samples showed a >90% decrease in IS area, when compared with the average IS area of the 
calibrators. The fluctuating IS areas indicate that the calibrators and QCs (including native QCs) used 
for the method validation and calibration of the method are not commutable with the patient 
samples. No clear reason could be identified why the patient samples behaved differently from the 
calibrators and QCs. Because of the non-commutability and because we cannot exclude stability 
issues in the patient samples, no formal quantification of the patient samples was undertaken. 
4. Conclusion 
The objective of this study was to evaluate dried blood as an alternative matrix for the quantification 
of APAP-protein adducts via UHPLC-MS/MS. For this purpose, methods for the quantification of 
APAP-protein adducts in dried blood and dried plasma VAMS samples were optimized and validated. 
In the method development, the sample preparation procedure was optimized, which included both 
a wash procedure and an enzymatic digestion step. The validation did not reveal any major issues 
with respect to the analysis of dried blood VAMS samples. However, the stability data indicated that, 
depending on the storage period and/or condition, there was potentially a decreased and more 
variable removal of APAP-Cysfree in the wash procedure, leading to increased concentrations of APAP-
Cys at several storage conditions. 
The spiking of APAP to blank blood revealed an additional formation of APAP-protein adducts, in 
which hepatic metabolization is not involved, and which is independent from incubation time or 
temperature. This additional formation of APAP-protein adducts appears to be related to the 
presence of the red blood cell fraction of the blood, more specifically red blood cell proteins, and 
contributes to a great extent to the total signal obtained for APAP-Cysprot  via the presented sample 
preparation procedure. Further research could possibly reveal the exact mechanism of this additional 
APAP-protein adduct formation, which could be related to the mechanism described by Potter and 
Hinson. 
The analysis of blood VAMS patient samples revealed that the IS area in patient samples is 
inconsistent both between and within patients, and we were unable to identify the cause of this 
issue. This apparent non-commutability, combined with the stability at RT which did not fulfill the 
acceptance criteria in the validation of the method, made the interpretation of results obtained from 
patient dried blood samples difficult in the context of risk assessment of APAP-induced 
hepatotoxicity. Hence, no quantitative results were reported. 
Taking into account all the above-mentioned observations, we conclude that dried blood is not a 
suitable matrix for the quantification of APAP-protein adducts via the measurement of the APAP-Cys 
digestion product, and the collection of plasma or serum, either in the form of a liquid sample or a 
dried microsample, for this purpose is advised. 
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Figure 1 Chromatogram obtained from blood and plasma native High QC VAMS samples without application 
of the wash procedure and without addition of pronase (A, plasma; B blood), after application of the wash 
procedure without addition of pronase (C, plasma; D, blood), and after application of the wash procedure 
with addition of pronase (E, plasma; F, blood). The black and grey lines are the signals for the APAP-Cys 
quantification and confirmation ion, respectively. Note the difference in scale. 
 
Figure 2 Determination of the protein loss in the wash steps via a Pierce BCA Protein assay. The relative protein 
loss compared to the total amount of blood proteins at different Hcts is determined for each wash cycle. Means 
(%) ± SD are shown (n=3). The total protein loss is the sum of the individual wash cycles. 























































































Figure 3 Effect of the Hct on the relative recovery of APAP-Cys from APAP-protein adducts. The relative 
recovery was determined for two analyte levels, and 5 Hct levels. The relative recovery is calculated by dividing 
the signal of the first analysis, by the sum of the signals of three consecutive analyses. The dotted lines indicate 
the ±15% acceptance criterion relative to the recoveries at intermediate Hct. Means (%) ± SD are shown (n=6). 
 
Figure 4 Area ratio analyte/IS obtained from VAMS samples prepared from blood spiked with APAP at three 
concentration levels (left graph) and prepared from blood at three Hct levels, spiked with 80 µg/mL APAP (right 
graph). Means ± SD are shown (n=3). 
 
 
Figure 5 Determination of APAP-Cys after adaption of the Hct of a non-spiked blood sample. The left panel 
depicts the area ratios analyte/IS obtained for the blood VAMS samples (n=1) and the right panel depicts the 
area ratios analyte/IS (means ± SD) for the VAMS samples (n=3) derived from the plasma obtained from the 

























































































































Figure 6 Results for the stability of blood and plasma VAMS samples after 6 months storage at -20 °C, 4 °C, and 
room temperature (RT). Data are presented as the mean % ± SD of the concentration measured at T0 (n=3). 
The dashed lines are the ±15% acceptance limits (LoA).  
Table 1 Accuracy (%bias), intra-day, and total precision (%RSD) data for spiked QC samples prepared at four 
concentration levels for blood and plasma VAMS samples (n=5x2), and precision data (%RSD) for native QC 
blood and plasma VAMS samples (n=4x2). 
Spiked QC 






Blood     
LLOQ 8.4 8.9 -1.4 
Low 6.3 8.0 -7.2 
Medium 5.0 6.1 -7.6 
High 5.2 7.2 -5.7 
Plasma    
LLOQ 8.8 8.8 -1.7 
Low 9.4 14.0 -3.5 
Medium 2.6 13.6 -2.5 
High 3.1 11.4 -4.1 
Native QC 






Blood     
Low 9.4 9.4 0.44 
Medium 7.6 12.6 3.25 
High 6.9 9.4 21.2 
Plasma 
LLOQ 6.6 10.2 0.065 
Low 10.8 14.4 0.15 
Medium 3.4 6.4 1.20 
High 3.8 14.6 8.10 
Table 2 Absolute and relative matrix effect at Low QC and High QC level in VAMS samples made from spiked 
blood from six different donors, one high and one low Hct blood sample, and plasma samples from six different 
donors 
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 Analyte IS compensated Analyte IS compensated 
Blood (n=8) 
Low 40 91 8.2 8.4 
High 43 95 7.0 4.2 
Plasma (n=6) 
Low 36 92 16 6.1 





Suppl. Table 1 Multiple reaction monitoring transitions and compound-specific MS parameters for APAP-Cys and 
its internal standard APAP-Cys-d5 (optimized following infusion) 














APAP-Cys Quantifier ion 271.20 140.1 39 10 33 10 
2.31  Confirmation 
ion 
271.20 182.2 39 10 21 12 
         
APAP-Cys-d5 Quantifier ion 276.25 143.1 39 10 33 10 
2.30  Confirmation 
ion 
276.25 182.2 39 10 21 12 
DP: declustering potential, EP: entrance potential, CE: collision energy, CXP: collision cell exit potential, 
Tr: retention time 
Suppl.Table 2 Source and gas parameters of the MS method 
CAD 12 psi 
CUR 40 psi 
GS 1 60 psi 
GS 2 30 psi 
ISV 3000 V 
TEM 450 °C 
CAD: collisionally activated dissociation gas, CUR: curtain gas, GS 1: nebulizer gas, GS 2: turbo gas, ISV: IonSpray 
voltage, TEM: temperature of the turbo gas 
 
Suppl. Figure 1 Effect of incubation time after spiking of blank blood with APAP and effect of storage 
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Suppl. Fig 2 Stability data obtained via the analysis of native QC samples for blood and plasma VAMS samples 
(n=3) after storage at -20 °C, 4 °C and room temperature (RT). Data are presented as the mean % ± SD of the 
concentration measured at T0. The dashed lines are the ±15% limits of acceptance (LoA). 
 
Suppl. Figure 3 Determination of the stability of processed samples. The stability of processed plasma (left 
graph) and blood (right graph) VAMS samples was evaluated after 3 days storage in the auto sampler 
(“Autosampler stability”), after 3 weeks storage at -80 °C (“Processed sample stability”) and three freeze-thaw 
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